<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4088">
  <stage>Registered</stage>
  <submitdate>11/09/2013</submitdate>
  <approvaldate>11/09/2013</approvaldate>
  <nctid>NCT01943045</nctid>
  <trial_identification>
    <studytitle>Phase 2 Study of NGM282 in Patients With Type 2 Diabetes</studytitle>
    <scientifictitle>A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Activity of NGM282 Administered for 28 Days to Patients With Type 2 Diabetes Mellitus</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>13-0102</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - NGM282
Other interventions - Placebo

Experimental: NGM282 Dose 1 - NGM Dose 1

Experimental: NGM282 Dose 2 - NGM Dose 2

Experimental: NGM282 Dose 3 - NGM Dose 3

Placebo Comparator: Placebo - Placebo


Other interventions: NGM282


Other interventions: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Fasting Plasma Glucose</outcome>
      <timepoint>28 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>HbA1c</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lipids</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males or females, between 18 and 70 years of age, inclusive

          -  BMI range of 24-40 kg/m2, inclusive

          -  No active coronary artery disease

          -  Resting heart rate in the range of 40-100 bpm</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Diagnosis of Type 1 diabetes

          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,
             food, or other substance</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>81</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC,WA</recruitmentstate>
    <hospital>NGM Clinical Study Site 6103 - Melbourne</hospital>
    <hospital>NGM Clinical Study Site 6104 - Melbourne</hospital>
    <hospital>NGM Clinical Study Site 6101 - Perth</hospital>
    <postcode> - Melbourne</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>NGM Biopharmaceuticals, Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>NGM Biopharmaceuticals Australia Pty Ltd</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in
      patients with Type 2 Diabetes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01943045</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Alex M DePaoli, MD</name>
      <address>NGM Biopharmaceuticals, Inc</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>